key: cord-0809330-ppjusz55
authors: Khatib, Mohamad Y.; Ananthegowda, Dore C.; Elshafei, Moustafa S.; El‐Zeer, Hani; Abdaljawad, Wael I.; Shaheen, Muhsen A.; Ibrahim, Abdulsalam S.; Abujaber, Ahmad A.; Soliman, Ahmed A.; Mohamed, Ahmed S.; Al‐Wraidat, Mohammad; Ahmed, Amna; Nashwan, Abdulqadir J.; Saad, Mohamed O.; Butt, Adeel A.; Al‐Maslamani, Muna A.; Al‐Mohammed, Ahmed
title: Predictors of mortality and morbidity in critically ill COVID‐19 patients: An experience from a low mortality country
date: 2022-05-17
journal: Health Sci Rep
DOI: 10.1002/hsr2.542
sha: a7c3cad2ca5170c85ebaf65a68c946244e3e5db4
doc_id: 809330
cord_uid: ppjusz55

BACKGROUND AND AIMS: Clinical characteristics and factors associated with mortality in patients admitted to the intensive care unit (ICU) in countries with low case fatality rates (CFR) are unknown. We sought to determine these in a large cohort of critically ill COVID‐19 patients in Qatar and explore the early mortality predictors. METHODS: We retrospectively studied the clinical characteristics and outcomes in patients admitted to the ICU at the national referral hospital for COVID‐19 patients in Qatar. Logistic regression analysis was used to determine factors associated with mortality. RESULTS: Between March 7 and July 16, 2020, a total of 1079 patients with COVID‐19 were admitted to the ICU. The median (IQR) age of patients was 50 (41–59) years. Diabetes (47.3%) and hypertension (42.6%) were the most common comorbidities. In‐hospital mortality was 12.6% overall and 25.9% among those requiring mechanical ventilation. Factors independently associated with mortality included older age ([OR]; 2.3 [95% CI; 1.92–2.75] for each 10‐year increase in age, p < 0.001), chronic kidney disease (OR; 1.9 [95% CI; 1.02–3.54], p = 0.04), active malignancy (OR; 6.15 [95% CI; 1.79–21.12], p = 0.004), lower platelet count at ICU admission (OR; 1.41 [95% CI; 1.13–1.75] for each 100 × 103/µl decrease, p = 0.002), higher neutrophil‐to‐lymphocyte ratio at admission (OR; 1.01 [95% CI; 1–1.02] for each 1‐ point increase, p = 0.016), higher serum ferritin level at admission (OR; 1.05 [(95% CI; 1.02–1.08] for each 500 µg/L increase, p = 0.002), and higher serum bilirubin level at admission (OR; 1.19 [95% CI; 1.04–1.36] for each 10 μmol/L increase, p = 0.01). CONCLUSIONS: The mortality rate among critically ill COVID‐19 patients is low in Qatar compared to other countries. Older age, chronic kidney disease, active malignancy, higher neutrophil‐to‐lymphocyte ratios, lower platelet counts, higher serum ferritin levels, and higher serum bilirubin levels are independent predictors of in‐hospital mortality.

The mortality rate among critically ill COVID-19 patients is low in Qatar compared to other countries. Older age, chronic kidney disease, active malignancy, higher neutrophil-to-lymphocyte ratios, lower platelet counts, higher serum ferritin levels, and higher serum bilirubin levels are independent predictors of in-hospital mortality.

ARDS, COVID-19, intensive care, mortality, SARS-CoV-2, Qatar

Coronavirus disease-19 primarily affects the respiratory system, though numerous other organs may be involved. 1 Case fatality rate (CFR) varies significantly among different countries ranging from as low as 0.05% in Singapore to around 8% in Mexico. 2 Higher mortality in persons with confirmed COVID-19 is associated with older age and the presence of comorbidities, such as diabetes mellitus type 2, hypertension, and impaired kidney function. 1, 2 However, demographic differences and the burden of comorbidities likely do not fully account for the vastly different case fatality rates in various countries, and other hosts, pathogen, or environmental factors may play a role. Access to care, particularly early hospital and intensive care unit (ICU) admission are plausible hypotheses that may affect mortality in these patients.

The first case of SARS-CoV-2 infection in Qatar was diagnosed on February 28, 2020, in a returning traveler. The first locally acquired case was diagnosed on March 7, 2020. Qatar has one of the highest infection rates per capita in the world but has also witnessed one of the lowest case fatality rates. 2 With a population of approximately 2.8 million persons, Qatar has recorded only 246 deaths among 145,672 patients (0.17%) by October 2021. 3 Patients who require intensive care have significantly higher mortality, ranging from 26% to 97% in various countries. [4] [5] [6] [7] [8] [9] [10] [11] While demographic characteristics and the presence of comorbidities are associated with higher mortality in patients admitted to the ICUs, the wide variation in mortality rate is not fully explained by these differences alone. These varied case fatality rates, for the same disease COVID-19, are probably not only because of the variance by virus or host but because of various environmental factors like the sudden surge of cases and nonavailability of resources and early access to critical care for all deserving cases. Our current knowledge is derived largely from countries with a high case fatality rate and predictors of mortality may be different in countries with a low case fatality rate.

In this study, we aim to describe the clinical characteristics and the complete outcomes of a large cohort of critically ill COVID-19 patients from a national referral hospital of Qatar and to explore the early predictors of in-hospital mortality among this cohort.

This study was conducted at Hazm Mebaireek General Hospital (HMGH), the main referral center for COVID-19 treatment in Qatar.

We retrospectively analyzed the data of patients with reverse transcriptase-polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infections who needed admission to the ICU between March 7 and July 16, 2020. The outcome data were collected up to August 18, 2020 

We included adult patients (18 years of age or older) admitted to HMGH ICU with a confirmed diagnosis of COVID-19 and complete outcome data, either discharge from hospital or mortality. Patients who stayed for less than 24 h in the ICU were excluded. ICU stay of at least 24 h is used to show any meaningful interventions from critical care which altered patients outcomes; if they die less than 24 h, it is probably more because of the ineffective support from prehospital care or already very sick at admission, or if discharged within 24-h, likely that they did not require ICU care at all from the beginning, hence 24-h cutoff limit.

Patient data, including sociodemographic information, clinical data, and laboratory data, were obtained from the electronic medical records. The primary outcome was in-hospital mortality. We collected data on the incidence of complications including venous thromboembolism, rhabdomyolysis, secondary infection and bleeding, and the requirement of organ support including invasive mechanical ventilation (IMV), vasopressor therapy, renal replacement therapy (RRT), and ECMO. Tracheostomy procedures were also captured.

Qualitative data are presented as counts with percentages and compared using the χ 2 test or Fisher's exact test, while quantitative data are presented as medians with interquartile range compared using the Mann-Whitney test. Potential predictor variables were 

During the study period, 1082 cases were admitted to ICU with COVID-19 and three were excluded as the length of stay in ICU was less than 24 h, hence we retrospectively analyzed the data of the re- (Table 1) Note: Continuous data are presented as median (interquartile range) and categorical data are presented as frequency (percentage).

Abbreviations: BMI, body mass index; PaO 2 /FiO 2 ratio, arterial oxygen partial pressure divided by the fraction of inspired oxygen; SOFA, sequential organ failure assessment. 11 In the USA, a mortality rate of 31%-50% in critically ill COVID-19 patients and 36%-88% in patients who required IMV has been reported. [4] [5] [6] In Europe, the reported mortality in critically ill COVID-19 patients ranged from 32% to 49%. [13] [14] [15] In a large randomized controlled trial that examined the benefit of dexamethasone for reducing mortality among COVID-19 patients, mortality among patients receiving IMV was 29.3%. 16 A systematic review and meta-analysis of 24 studies, including 10,150 patients with complete ICU data, found a pooled ICU mortality rate of 41.6%. 17 A possible explanation of the lower mortality in the current study might be the higher percentage of steroid usage since the initial phases of the pandemic, which was later proven beneficial by randomized controlled trials. 16, 18 In the current study, 85.6% of patients research is needed to explore whether genetic or environmental factors may explain such differences in disease outcomes.

In the current study, hypertension and diabetes mellitus were the most common comorbidities among critically ill COVID-19 patients (47.3% and 42.6%, respectively). The most common comorbidities in previous studies were also hypertension and diabetes mellitus. 5, 10, 15, 16, 19, 20 The association of these diseases with mortality varied among reported literature, with some studies suggesting systemic hypertension is significantly associated with mortality 11, [20] [21] [22] and others associating diabetes with mortality. [23] [24] [25] Despite being more common in the patients who died in our study cohort, hypertension and diabetes were not independently associated with higher mortality after adjustment for other confounders. and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

Dore C. Ananthegowda http://orcid.org/0000-0001-7408-5746

Prevalence, clinical manifestations, and biochemical data of hypertensive versus normotensive symptomatic patients with COVID-19: a comparative study

WHO Coronavirus Disease (COVID-19) Dashboard. Accessed

Ministry of Public Health COVID-19. Dashboard, Qatar

Covid-19 in critically ill patients in the seattle region-case series

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

ICU and ventilator mortality among critically ill adults with coronavirus disease 2019

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region

Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Characteristics of hospitalized adults With COVID-19 in an integrated health care system in California

Clinical course and outcomes of 344 intensive care patients with COVID-19

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: initial report of the international RISC-19-ICU prospective observational cohort

Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS

Risk Factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy

Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies

Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX Randomized Clinical Trial

clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: a comparative study

Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in

Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome

Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis

Risk factors associated with mortality in hospitalized patients with SARS-CoV-2 infection. A prospective, longitudinal, unicenter study in Reus

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Predictors of mortality and morbidity in critically ill COVID-19 patients: an experience from a low mortality country